AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25500831
Drug: Injecting (11)C-dLop
RxNorm normalized name: (11)C-choline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injecting (11)C-dLop after intravenous tariquidar infusion (up to 6 mg/kg)
Trial: 25500831
Drug: Oral tariquidar
RxNorm normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tariquidar
Trial: 25501494
Drug: Intrathecal injection
RxNorm normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal injection of bupivacaine 1.75 mg and fentanyl 15 μg
Trial: 25501547
Drug: NKG2D receptor
RxNorm normalized name: NKG2D CAR-NK Cell
DrugBank: NKG2D-ACE2 CAR-NK Cell (DB15727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKG2D receptor expression on NK cells, CTLs, and NKT cells in alcoholic hepatitis
Trial: 25501820
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori eradication treatment consisting of lansoprazole 30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg orally twice daily for a week.
Trial: 25502858
Drug: Simplified negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplified negative-pressure wound therapy
Trial: 25502863
Drug: Amatuximab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amatuximab (200 mg/m2)
Trial: 25502863
Drug: Amatuximab (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amatuximab (50 mg/m2)
Trial: 25503302
Drug: Vandetanib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib (200 mg) plus sirolimus (2 mg)
Trial: 25503750
Drug: Combined inhaled
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined inhaled medication
Trial: 25503901
Drug: Implant-supported restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported restorative therapy
Trial: 25504157
Drug: Desmopressin tablet
RxNorm normalized name: desmopressin Sublingual Tablet
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin tablet (once daily)
Trial: 25504813
Drug: Korean Red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean Red Ginseng at doses of 3 g/day
Trial: 25505693
Drug: Add-on lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on lithium (600 to 1,800 mg/day)
Trial: 25505693
Drug: Lithium in
RxNorm normalized name: Product containing lithium in cutaneous dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium in combination with quetiapine XR
Trial: 25510388
Drug: MCC-CRM followed
RxNorm normalized name: Trastuzumab-MCC-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MCC-CRM followed by MCC-TT vaccine
Trial: 25510388
Drug: Two MCC-CRM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two MCC-CRM vaccines
Trial: 25510388
Drug: Two MCC-TT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two MCC-TT vaccines
Trial: 25510388
Drug: MCC-TT followed
RxNorm normalized name: Trastuzumab-MCC-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MCC-TT followed by MCC-CRM vaccine
Trial: 25511105
Drug: Serelaxin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serelaxin (30 μg kg(-1) day(-1) via intravenous infusion for 24 hours)
Trial: 25511129
Drug: Hypnotic relaxation
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic relaxation suggestion
Trial: 25511783
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with stages 3-4 renal dysfunction (GFR <60 mL/min/1.73 m(2))
Trial: 25512030
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and trastuzumab neoadjuvant chemotherapy (NC) for 24 weeks, followed by 1 year adjuvant trastuzumab ± hormonal and/or radio-therapy.
Trial: 25512030
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and trastuzumab neoadjuvant chemotherapy (NC) for 24 weeks.
Trial: 25512030
Drug: Trastuzumab-mediated antibody-dependent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab-mediated antibody-dependent cell cytotoxicity (ADCC).
Trial: 25512422
Drug: Rifapentine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifapentine (600 mg) with bedaquiline (400 mg)
Trial: 25512422
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg) with bedaquiline (400 mg)
Trial: 25512839
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (three weekly sessions for four weeks)
Trial: 25512839
Drug: Conventional occlusal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occlusal splint therapy (worn for four weeks)
Trial: 25512839
Drug: Massage +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage + Conventional occlusal splint therapy (three weekly sessions for four weeks and occlusal splint worn for four weeks)
Trial: 25512839
Drug: Silicone occlusal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone occlusal splint therapy (worn for four weeks)
Trial: 25512874
Drug: Closed loop
RxNorm normalized name: Povidone Iodine 7.5% Topical application Liquid [OPERAND CLOSED LOOP PVP-I SCRUB]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed loop with diluted insulin aspart (CL_Dil; 20 IU/mL)
Trial: 25512874
Drug: Closed loop
RxNorm normalized name: Povidone Iodine 7.5% Topical application Liquid [OPERAND CLOSED LOOP PVP-I SCRUB]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed loop with standard aspart (CL_Std; 100 IU/mL)
Trial: 25514427
Drug: Low IL-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low IL-8 levels (L group, n = 335)
Trial: 25516773
Drug: Paracetamol/naproxen (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol/naproxen (n = 35)
Trial: 25516773
Drug: Paracetamol/CR oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol/CR oxycodone for 24 hours (n = 35)
Trial: 25516773
Drug: Paracetamol/CR oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol/CR oxycodone for 48 hours (n = 35)
Trial: 25516774
Drug: Diclofenac sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac sustained release 75 mg once daily
Trial: 25516890
Drug: MK-2206 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 at 135 mg weekly and selumetinib at 100 mg once daily
Trial: 25518864
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Morris-Marshall score and S-100B bulk release
Trial: 25519810
Drug: Bimatoprost 0.01%
RxNorm normalized name: BIMATOPROST 0.01% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.01% once daily
Trial: 25521357
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bevacizumab and first-line paclitaxel with favorable genetic profile (VEGFR-2 rs11133360 and IL-8 rs4073)
Trial: 25521357
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bevacizumab and first-line paclitaxel with unfavorable genetic profile (VEGFR-2 rs11133360 and IL-8 rs4073)
Trial: 25521398
Drug: Dacomitinib at
RxNorm normalized name: dacomitinib
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dacomitinib at 45 mg once daily
Trial: 25521773
Drug: Standard intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intraoperative dose of morphine
Trial: 25523604
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea gel (test group)
Trial: 25524800
Drug: Blinatumomab (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (9 μg/day for the first 7 days and 28 μg/day thereafter) by continuous intravenous infusion over 4 weeks every 6 weeks (up to five cycles)
Trial: 25526776
Drug: 6-mercaptopurine (6MP)
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine (6MP) 55 mg/m² per day and methotrexate 15 mg/m² per week
Trial: 25527007
Drug: wXELIRI (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wXELIRI (weekly irinotecan 90 mg/m² on day 1 and capecitabine 1200 mg/m² twice daily on days 1-5)
Trial: 25527007
Drug: wXELIRI (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wXELIRI (weekly irinotecan and capecitabine)
Trial: 25529193
Drug: BI 831266
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 831266 (130 mg)
Trial: 25529193
Drug: BI 831266
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 831266 (various doses 4-130 mg)
Trial: 25529193
Drug: BI 831266
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 831266 (various doses)
Trial: 25529193
Drug: BI 831266
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 831266 (32 mg)
Trial: 25529339
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose MSCs (1 million cells/kg PBW)
Trial: 25529339
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose MSCs (5 million cells/kg PBW)
Trial: 25529339
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose MSCs (10 million cells/kg PBW)
Trial: 25529339
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of MSCs
Trial: 25531808
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) injection in forearm and deltoid
Trial: 25531808
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) injection in deltoid
Trial: 25531808
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) injection in forearm
Trial: 25531960
Drug: ALO-02 (oxycodone-hydrochloride/naltrexone-hydrochloride)
RxNorm normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALO-02 (oxycodone-hydrochloride/naltrexone-hydrochloride)
Trial: 25533729
Drug: Twelve-week weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twelve-week weight loss intervention, details on dosage and specific methods not provided.
Trial: 25533886
Drug: SBT/ABPC 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBT/ABPC 3 g QID intravenously for 3-14 days
Trial: 25535009
Drug: G allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G allele of rs7549184
Trial: 25535041
Drug: HIV medication
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV medication adherence intervention program
Trial: 25535294
Drug: US smokers;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US smokers; urine NNAL excretion
Trial: 25535398
Drug: Intraoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiotherapy (IORT) added to standard therapy
Trial: 25538323
Drug: Exogenous intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous intravenous administrations of GLP-1
Trial: 25538323
Drug: Exogenous intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous intravenous administrations of GIP
Trial: 25538323
Drug: Exogenous intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous intravenous administrations of GLP-1 and GIP
Trial: 25540064
Drug: Bosutinib 500
RxNorm normalized name: bosutinib 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 500 mg/day (n = 63)
Trial: 25540064
Drug: Bosutinib 500
RxNorm normalized name: bosutinib 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 500 mg/day (n = 28, CP 2L)
Trial: 25540064
Drug: Bosutinib 500
RxNorm normalized name: bosutinib 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 500 mg/day (n = 7, advanced-phase 2L)
Trial: 25540064
Drug: Bosutinib 500
RxNorm normalized name: bosutinib 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 500 mg/day (n = 11, 3L)
Trial: 25545153
Drug: G-CSF priming,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF priming, clofarabine (30 mg m(-2) day(-1) × 5), and cytarabine (2 g m(-2) day(-1) × 5)
Trial: 25545153
Drug: G-CSF priming,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF priming, clofarabine, and cytarabine
Trial: 25546176
Drug: Pre-bolus low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-bolus low-dose contrast injection (1.3 mL and 0.05 mmol/kg of gadobenate dimeglumine)
Trial: 25552401
Drug: 250 mg/day
RxNorm normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day gefitinib and 400 mg/day vorinostat
Trial: 25552401
Drug: 250 mg/day
RxNorm normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day gefitinib and 400 mg/day vorinostat in EGFR-mutant NSCLC
Trial: 25553059
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity index (SI) calculated from the minimal model.
Trial: 25555214
Drug: Biological pathways
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological pathways and genes associated with adipose tissue lipogenesis in MNO subjects
Trial: 25555214
Drug: Biological pathways
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological pathways and genes associated with adipose tissue lipogenesis in MAO subjects
Trial: 25555267
Drug: Calcium-channel blockers
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-channel blockers use
Trial: 25555354
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg/day) for 7 days
Trial: 25555354
Drug: Both aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both aspirin and EPA+DHA for another 7 days
Trial: 25555420
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg orally once daily for 28-day cycles until disease progression or limiting toxicities
Trial: 25556716
Drug: IGN523 (anti-CD98
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGN523 (anti-CD98 antibody)
Trial: 25556837
Drug: Concomitant CYP3A4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant CYP3A4 inhibitors
Trial: 25557329
Drug: Multimodal analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesic regimen (gabapentin, ketorolac, dexamethasone, acetaminophen, ibuprofen)
Trial: 25558980
Drug: Intraoperative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative dose of morphine
Trial: 25560174
Drug: Dalfampridine-ER 5
RxNorm normalized name: Dalfampridine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine-ER 5 mg
Trial: 25560174
Drug: Dalfampridine-ER 10
RxNorm normalized name: Dalfampridine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine-ER 10 mg
Trial: 25560203
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural anesthesia using 0.375% or 0.5% ropivacaine 15 mL, followed by continuous infusion of 0.15% ropivacaine 2 mL·hr(-1) with fentanyl 8 μg·hr(-1) postoperatively
Trial: 25560712
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy stopped after negative D-dimer test results
Trial: 25560712
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy stopped after negative D-dimer test results in men
Trial: 25560712
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy stopped after negative D-dimer test results in women not associated with estrogen therapy
Trial: 25560712
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy stopped after negative D-dimer test results in women associated with estrogen therapy
Trial: 25563429
Drug: Lestaurtinib 140
RxNorm normalized name: Lestaurtinib
DrugBank: Lestaurtinib (DB06469)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lestaurtinib 140 mg twice daily (maximum tolerated dose)
Trial: 25563429
Drug: Lestaurtinib (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lestaurtinib (doses lower than 140 mg)
Trial: 25565635
Drug: Myoblast preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myoblast preparations with genomic abnormalities
Trial: 25566367
Drug: Culturally specific
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally specific group cognitive behavioral therapy (CS-CBT)
Trial: 25566367
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group cognitive behavioral therapy (control)
Trial: 25566367
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups receive transdermal nicotine patch (TNP) for 8 weeks
Trial: 25566369
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) and Mindfulness-Based Cognitive Therapy (MBCT)
Trial: 25566391
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (16 sessions)
Trial: 25566998
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of daily living (ADL) part of the Friedreich's Ataxia Rating Scale
Trial: 25567425
Drug: Antipsychotic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medications (olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone)
Trial: 25567425
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment (after 6 months)
Trial: 25568347
Drug: R-MPV chemotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-MPV chemotherapy (rituximab, methotrexate 3.5 g/m(2), procarbazine, vincristine)
Trial: 25572329
Drug: Panobinostat 30
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat 30 mg 3 times per week, every other week, in combination with bevacizumab 10 mg/kg every other week
Trial: 25572917
Drug: Bortezomib 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.6 mg/m² intravenously once-weekly for six cycles with dexamethasone 40 mg on the day of and day after bortezomib
Trial: 25574042
Drug: Silicone hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone hydrogel daily disposable lenses (SiHyDD)
Trial: 25574042
Drug: Hydrogel daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel daily disposable lenses (HydDD)
Trial: 25574088
Drug: TNBS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNBS treatment in rats
Trial: 25574704
Drug: Maternal estimated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal estimated insulin resistance in the first half of pregnancy
Trial: 25575538
Drug: Pomalidomide plus
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide plus low-dose dexamethasone (Pom-Dex)
Trial: 25579459
Drug: Neoadjuvant anthracycline
RxNorm normalized name: methacycline
DrugBank: Metacycline (DB00931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant anthracycline regimens followed by nanoparticle albumin-bound paclitaxel (nab-PTX) 260 mg/m² plus trastuzumab, administered every 3 weeks for 4 cycles.
Trial: 25581108
Drug: Nonvitamin K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonvitamin K antagonist oral anticoagulants
Trial: 25581108
Drug: Nonvitamin K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonvitamin K antagonist oral anticoagulants started early (median 4 days after stroke onset)